---
title: "Cobenfy (xanomeline and trospium chloride) in schizophrenia: Safety questions"
description: "Safety questions on Cobenfy (xanomeline and trospium chloride) in schizophrenia, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Monitoring, Safety management, and Warnings. Questions: What monitoring does COBENFY require before and during treatment? Does COBENFY raise liver enzymes? What are the most common COBENFY side effects? Does COBENFY cause nausea and vomiting? 9 further questions follow. 13 questions quoted from 4 sources."
canonical: "https://www.evicenter.com/medical-information/cobenfy--schizophrenia/safety"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Cobenfy (xanomeline and trospium chloride) in schizophrenia: Safety questions

Manufacturer: Bristol-Myers Squibb Company  
Prescribing information: [Cobenfy](https://packageinserts.bms.com/pi/pi_cobenfy.pdf)

## Monitoring

<a id="cobenfy-baseline-assessments"></a>

### What monitoring does COBENFY require before and during treatment?

> “Assess liver enzymes, bilirubin, and heart rate before starting COBENFY and as clinically indicated.<sup>1</sup>”

Source: [COBENFY: Dosing COBENFY™ (xanomeline and trospium chloride) | For HCPs, captured 2026-11-08](https://www.cobenfyhcp.com/dosing#:~:text=Assess%20liver%20enzymes%2C%20bilirubin%2C%20and,starting%20COBENFY%20and%20as%20clinically)

> “Discontinue COBENFY in the presence of signs or symptoms of substantial liver injury such as jaundice, pruritus, or alanine aminotransferase levels more than five times the upper limit of normal or five times baseline values.”

Source: [COBENFY: Dosing COBENFY™ (xanomeline and trospium chloride) | For HCPs, captured 2026-11-08](https://www.cobenfyhcp.com/dosing#:~:text=Discontinue%20COBENFY%20in%20the%20presence,or%20five%20times%20baseline%20values.)

> “In patients taking COBENFY, monitor for symptoms of urinary retention, including urinary hesitancy, weak stream, incomplete bladder emptying, and dysuria.”

Source: [COBENFY: The Safety of COBENFY™ (xanomeline and trospium chloride) | For HCPs, captured 2026-11-08](https://www.cobenfyhcp.com/safety#:~:text=In%20patients%20taking%20COBENFY%2C%20monitor,incomplete%20bladder%20emptying%2C%20and%20dysuria.)

## Safety

<a id="cobenfy-liver-enzymes"></a>

### Does COBENFY raise liver enzymes?

> “Liver Enzyme Elevations
> In the 5-week, placebo-controlled schizophrenia studies, the proportions of patients with ALT 
> or AST elevations of ≥3 times the upper limits of the normal reference range were 2.8% (6/214) 
> for COBENFY-treated patients compared to 0.4% (1/224) of placebo-treated patients. Twenty-
> five (1.6%) of the total 1,594 subjects exposed to COBENFY had elevated liver enzymes. The 
> majority of liver enzyme elevations occurred within the first month of treatment and resolved 
> with continued COBENFY use, suggestive of liver adaptation; some cases required treatment 
> interruption, and one was associated with an increase in bilirubin.”

Source: [COBENFY: Prescribing information, page 3, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_cobenfy.pdf#page=3)

> “Risk of Use in Patients with Biliary Disease: In clinical studies with COBENFY, transient increases in liver enzymes with rapid decline occurred, consistent with transient biliary obstruction due to biliary contraction and possible gallstone passage.”

Source: [COBENFY: The Safety of COBENFY™ (xanomeline and trospium chloride) | For HCPs, captured 2026-11-08](https://www.cobenfyhcp.com/safety#:~:text=Risk%20of%20Use%20in%20Patients%20with%20Biliary,contraction%20and%20possible%20gallstone%20passage.)

<a id="cobenfy-common-adverse-reactions"></a>

### What are the most common COBENFY side effects?

> “Most Common Adverse Reactions (≥5% and at least twice placebo): nausea, dyspepsia, constipation, vomiting, hypertension, abdominal pain, diarrhea, tachycardia, dizziness, and gastroesophageal reflux disease.”

Source: [COBENFY: The Safety of COBENFY™ (xanomeline and trospium chloride) | For HCPs, captured 2026-11-08](https://www.cobenfyhcp.com/safety#:~:text=Most%20Common%20Adverse%20Reactions%20%28%E2%89%A55%25,dizziness%2C%20and%20gastroesophageal%20reflux%20disease.)

> “Table 1:	
> Adverse Reactions Reported in ≥2% of COBENFY-Treated Patients and 
> Greater than Rate of Placebo in Two 5-week Schizophrenia Trials
> COBENFY 
> (N=251)
> Placebo 
> (N=253)
> Nausea
> 19%
> 4%
> Dyspepsia <sup>a</sup> 
> 18%
> 5%
> Constipation
> 17%
> 7%
> Vomiting
> 15%
> 1%
> Hypertension <sup>b</sup> 
> 11%
> 2%
> Abdominal Pain <sup>c</sup> 
> 8%
> 4%
> Diarrhea 
> 6%
> 2%
> Tachycardia <sup>d</sup> 
> 5%
> 2%
> Dizziness
> 5%
> 2%
> Gastroesophageal reflux disease
> 5%
> <1%
> Dry mouth
> 4%
> 2%
> Somnolence
> 3%
> 2%
> Vision blurred
> 3%
> 0%
> Salivary hypersecretion
> 2%
> 0%
> Orthostatic hypotension
> 2%
> 1%
> Cough <sup>e</sup> 
> 2%
> 1%
> Extrapyramidal symptoms (EPS), 
> non-akathisia <sup>f</sup> 
> 2%
> <1%
> a	 Dyspepsia includes dyspepsia, esophageal discomfort
> b	 Hypertension includes hypertension, blood pressure increased, labile hypertension, orthostatic 
> hypertension
> c	 Abdominal Pain includes abdominal discomfort, abdominal pain upper, abdominal pain, 
> abdominal pain lower, abdominal tenderness
> d	 Tachycardia includes tachycardia, heart rate increased, sinus tachycardia
> e	 Cough: includes cough, productive cough
> <sup>f</sup>	 EPS (non-akathisia) includes dyskinesia, drooling, dystonia, extrapyramidal disorder, muscle 
> contraction involuntary, muscle spasms”

Source: [COBENFY: Prescribing information, page 3, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_cobenfy.pdf#page=3)

> “6% of patients treated with COBENFY and 4% of patients treated with placebo discontinued due to adverse reactions in the 5-week, placebo-controlled studies.”

Source: [COBENFY: Dosing COBENFY™ (xanomeline and trospium chloride) | For HCPs, captured 2026-11-13](https://www.cobenfyhcp.com/dosing?tabKey=setexpectations#:~:text=6%25%20of%20patients%20treated%20with,in%20the%205%2Dweek%2C%20placebo%2Dcontrolled%20studies.)

On the page, select: SET EXPECTATIONS

<a id="cobenfy-nausea-vomiting"></a>

### Does COBENFY cause nausea and vomiting?

> “Table 1:	
> Adverse Reactions Reported in ≥2% of COBENFY-Treated Patients and 
> Greater than Rate of Placebo in Two 5-week Schizophrenia Trials
> COBENFY 
> (N=251)
> Placebo 
> (N=253)
> Nausea
> 19%
> 4%
> Dyspepsia <sup>a</sup> 
> 18%
> 5%
> Constipation
> 17%
> 7%
> Vomiting
> 15%
> 1%”

Source: [COBENFY: Prescribing information, page 3, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_cobenfy.pdf#page=3)

> “Initial onset of nausea and vomiting was mild to moderate*<sup>†</sup>, transient, and generally declined with continued titration to 125 mg/30 mg<sup>1,12,13</sup>
>
> Nausea and vomiting initial occurrences generally declined after the titration period (EMERGENT-2 & -3)<sup>1,12</sup>
>
> Nausea and vomiting were reported by 19% and 15% of patients, respectively<sup>1</sup>
>
> ~70% of nausea and vomiting were mild<sup>12</sup>”

Source: [COBENFY: Dosing COBENFY™ (xanomeline and trospium chloride) | For HCPs, captured 2026-11-13](https://www.cobenfyhcp.com/dosing?tabKey=setexpectations#:~:text=Initial%20onset%20of%20nausea%20and,of%20nausea%20and%20vomiting%20were)

On the page, select: SET EXPECTATIONS

> “<sup>†</sup>	EMERGENT-2 & -3, 13.9% and 5.2% of patients treated with COBENFY had mild or moderate nausea, respectively, and 10.4% and 4.8% had mild or moderate vomiting, respectively. No patients had severe nausea or vomiting.<sup>12</sup>”

Source: [COBENFY: Dosing COBENFY™ (xanomeline and trospium chloride) | For HCPs, captured 2026-11-13](https://www.cobenfyhcp.com/dosing?tabKey=setexpectations#:~:text=EMERGENT%2D2%20%26%20%2D3%2C%2013.9%25%20and,patients%20had%20severe%20nausea%20or)

On the page, select: SET EXPECTATIONS

<a id="cobenfy-long-term-adverse-reactions"></a>

### Which less common COBENFY side effects (2% to under 5%) were seen in short- and long-term trials?

> “Additional pooled adverse reactions in short- or long-term trials with rates ≥2% and <5%: anxiety (3%, 3%); vision blurred (3%, 2%); hyperhidrosis (2%, 4%); weight increased (2%, 3%); salivary hypersecretion (2%, 3%); akathisia (2%, 1%); cough<sup>e</sup> (2%, 2%); extrapyramidal symptoms (EPS), non-akathisia<sup>f</sup> (2%, 1%); orthostatic hypotension (2%, 1%); agitation (2%, <1%); back pain (1%, 4%); upper respiratory tract infection (<1%, 3%); urinary tract infection (<1%, 3%); decreased appetite (<1%, 2%); urinary retention (<1%, 2%).
>
> In long-term trials, TEAEs were primarily mild to moderate (96%).<sup>7</sup>”

Source: [COBENFY: The Safety of COBENFY™ (xanomeline and trospium chloride) | For HCPs, captured 2026-11-08](https://www.cobenfyhcp.com/safety#:~:text=Additional%20pooled%20adverse%20reactions%20in,were%20primarily%20mild%20to%20moderate)

> “*	Data are exploratory from an ad hoc analysis and represent long-term data as of April 17, 2023.”

Source: [COBENFY: The Safety of COBENFY™ (xanomeline and trospium chloride) | For HCPs, captured 2026-11-08](https://www.cobenfyhcp.com/safety#:~:text=Data%20are%20exploratory%20from%20an%20ad%20hoc%20analysis%20and%20represent%20long%2Dterm%20data%20as%20of%20April%2017%2C%202023.,-Safety%20population%20defined)

> “Safety population defined as all participants who received ≥1 dose of trial medication.<sup>7</sup>”

Source: [COBENFY: The Safety of COBENFY™ (xanomeline and trospium chloride) | For HCPs, captured 2026-11-08](https://www.cobenfyhcp.com/safety#:~:text=Safety%20population%20defined%20as%20all%20participants%20who%20received%20%E2%89%A51%20dose%20of%20trial)

Note: The page shows the more common pooled adverse reactions as a chart, which is not quoted. The page text does not label which of the two rates given for each reaction is short-term and which is long-term.

<a id="cobenfy-boxed-warning"></a>

### Does COBENFY have a boxed warning?

> “No Boxed Warning<sup>8</sup>”

Source: [COBENFY: The Safety of COBENFY™ (xanomeline and trospium chloride) | For HCPs, captured 2026-11-08](https://www.cobenfyhcp.com/safety#:~:text=No%20Boxed)

<a id="cobenfy-overdose"></a>

### What happens with a COBENFY overdose?

> “Overdose of COBENFY may produce cholinergic, anticholinergic or a combination of cholinergic 
> and anticholinergic signs and symptoms:
> 	•
> Cholinergic Signs and Symptoms: seizures, vomiting, diarrhea, abdominal pain, 
> hyperhidrosis, salivary hypersecretion, and hypotension possibly preceded by 
> hypertension.
> 	•
> Anticholinergic Signs and Symptoms (geriatric patients may be more susceptible): 
> delirium, agitation, garbled speech, dizziness, hypertension, tachycardia, dry mouth 
> and eyes, ileus, blurred vision, and urinary retention.
> Consider calling the Poison Help Line 1-800-222-1222 or a medical toxicologist for specific 
> treatment recommendations.”

Source: [COBENFY: Prescribing information, page 5, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_cobenfy.pdf#page=5)

<a id="cobenfy-urinary-retention"></a>

### Can COBENFY cause urinary retention?

> “Risk of Urinary Retention: COBENFY can cause urinary retention. Geriatric patients and patients with clinically significant bladder outlet obstruction and incomplete bladder emptying (e.g., patients with benign prostatic hyperplasia (BPH), diabetic cystopathy) may be at increased risk of urinary retention.
>
> COBENFY is contraindicated in patients with pre-existing urinary retention and is not recommended in patients with moderate or severe renal impairment.
>
> In patients taking COBENFY, monitor for symptoms of urinary retention, including urinary hesitancy, weak stream, incomplete bladder emptying, and dysuria. Instruct patients to be aware of the risk and promptly report symptoms of urinary retention to their healthcare provider. Urinary retention is a known risk factor for urinary tract infections. In patients with symptoms of urinary retention, consider reducing the dose of COBENFY, discontinuing COBENFY, or referring patients for urologic evaluation as clinically indicated.”

Source: [COBENFY: The Safety of COBENFY™ (xanomeline and trospium chloride) | For HCPs, captured 2026-11-08](https://www.cobenfyhcp.com/safety#:~:text=Risk%20of%20Urinary%20Retention%3A%20COBENFY,urologic%20evaluation%20as%20clinically%20indicated.)

<a id="cobenfy-weight-gain"></a>

### Does COBENFY cause weight gain?

> “No warnings or precautions for metabolic changes, including weight gain<sup>8</sup>”

Source: [COBENFY: The Safety of COBENFY™ (xanomeline and trospium chloride) | For HCPs, captured 2026-11-08](https://www.cobenfyhcp.com/safety#:~:text=No%20warnings%20or%20precautions%20for%20metabolic%20changes%2C%20including%20weight)

> “~96% OF PATIENTS DID NOT EXPERIENCE CLINICALLY SIGNIFICANT WEIGHT GAIN<sup>9</sup>*
>
> Weight Change Over the 52-Week Treatment Period (pooled data)<sup>9</sup>
> EMERGENT -4 & -5
>
> *	Defined as ≥7% increase in body weight.<sup>9</sup>”

Source: [COBENFY: The Safety of COBENFY™ (xanomeline and trospium chloride) | For HCPs, captured 2026-11-08](https://www.cobenfyhcp.com/safety#:~:text=~96%25%20OF%20PATIENTS%20DID%20NOT,as%20%E2%89%A57%25%20increase%20in%20body)

Note: The ~96% figure comes from pooled data of the 52-week, open-label EMERGENT-4 and EMERGENT-5 trials named in the page reference list; the page reports it without a placebo or active comparator group. About 4% of patients had a weight increase of 7% or more.

<a id="cobenfy-movement-disorders"></a>

### Does COBENFY cause movement disorders or extrapyramidal symptoms (EPS)?

> “No warnings or precautions for any movement disorder<sup>8</sup>”

Source: [COBENFY: The Safety of COBENFY™ (xanomeline and trospium chloride) | For HCPs, captured 2026-11-08](https://www.cobenfyhcp.com/safety#:~:text=No%20warnings%20or%20precautions%20for%20any%20movement)

> “Movement Disorders With COBENFY<sup>7</sup>
> Pooled Data From Long-Term Trials (N=718)<sup>*</sup>
>
> <1% of patients taking COBENFY discontinued treatment due to EPS.<sup>7</sup>
> Mean change across movement disorder scales (AIMS, BARS, SAS) was -0.2.<sup>7</sup>”

Source: [COBENFY: The Safety of COBENFY™ (xanomeline and trospium chloride) | For HCPs, captured 2026-11-08](https://www.cobenfyhcp.com/safety#:~:text=Pooled%20Data%20From%20Long%2DTerm%20Trials,scales%20%28AIMS%2C%20BARS%2C%20SAS%29%20was)

Note: The long-term trials of COBENFY were 52-week, open-label studies.

<a id="cobenfy-formal-contraindications"></a>

### What are the contraindications for COBENFY?

> “COBENFY is contraindicated in patients with: urinary retention; moderate or severe (Child-Pugh Class B or C) hepatic impairment; gastric retention; history of hypersensitivity to COBENFY or trospium chloride—angioedema has been reported with COBENFY and trospium chloride; and untreated narrow-angle glaucoma.”

Source: [COBENFY: The Safety of COBENFY™ (xanomeline and trospium chloride) | For HCPs, captured 2026-11-08](https://www.cobenfyhcp.com/safety#:~:text=COBENFY%20is%20contraindicated%20in%20patients,chloride%3B%20and%20untreated%20narrow%2Dangle%20glaucoma.)

## Safety management

<a id="cobenfy-nausea-vomiting-management"></a>

### How are nausea and vomiting on COBENFY managed?

> “Consider prescribing antiemetics prophylactically<sup>12</sup>*
>
> *	Ondansetron was the antiemetic most used in COBENFY clinical trials. 4% of patients were prescribed ondansetron as needed in EMERGENT-1, -2, & -3 clinical trials (pooled data).<sup>12</sup>”

Source: [COBENFY: Dosing COBENFY™ (xanomeline and trospium chloride) | For HCPs, captured 2026-11-13](https://www.cobenfyhcp.com/dosing?tabKey=setexpectations#:~:text=Consider%20prescribing%20antiemetics,%26%20%2D3%20clinical%20trials%20%28pooled)

On the page, select: SET EXPECTATIONS

## Warnings

<a id="cobenfy-warnings-precautions"></a>

### What are the COBENFY warnings and precautions?

> “COBENFY has warnings and precautions for<sup>8</sup>:
>
> Risk of:
> urinary retention
> use in patients with hepatic impairment
> use in patients with biliary disease
> angioedema
> use in patients with narrow-angle glaucoma
> Decreased gastrointestinal motility
> Increases in heart rate
> Anticholinergic adverse reactions in patients with renal impairment
> Central nervous system effects”

Source: [COBENFY: The Safety of COBENFY™ (xanomeline and trospium chloride) | For HCPs, captured 2026-11-08](https://www.cobenfyhcp.com/safety#:~:text=COBENFY%20has%20warnings%20and%20precautions,Central%20nervous%20system%20effects)

## Related pages
- [Medical information: Cobenfy (xanomeline and trospium chloride): Schizophrenia](https://www.evicenter.com/medical-information/cobenfy--schizophrenia)
- [Indication](https://www.evicenter.com/medical-information/cobenfy--schizophrenia/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/cobenfy--schizophrenia/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/cobenfy--schizophrenia/clinical-trials)
- [Specific populations](https://www.evicenter.com/medical-information/cobenfy--schizophrenia/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/cobenfy--schizophrenia/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/cobenfy--schizophrenia/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/cobenfy--schizophrenia/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/cobenfy--schizophrenia/access-and-coverage)
